Professor Domenic Lam received a Bachelor of Science in Mathematics, a Master of Science in Physics from the University of British Columbia and a D.Phil in Medical Biophysics from the University of Toronto. Dr. Lam obtained his bachelor, master, and doctorate degrees by the age of 22 and had the good fortune to study under two Nobel Laureates (Profs. T. Wiesel and D. Hubel) at Harvard Medical School. Dr. Lam is a former Assistant Professor of Harvard Medical School, and a former Professor of Biotechnology, Cell Biology and Ophthalmology at Baylor College of Medicine, Houston, Texas. Dr. Lam became the Founding Director of the Hong Kong Institute of Biotechnology and held the position until 1992. He was appointed Honorary Professor at the Chinese Academy of Science and Visiting Professor at Zhongshan University of Medical Sciences. Dr. Lam was subsequently appointed a Member of the Scientific Advisory Board of China’s National Institute of Biological Sciences, the National Biotechnology Center of the Chinese Ministry of Technology and the Shanghai Fenglin Biomedical Center, as well as Honorary Professor at the University of Hong Kong.
Dr. Lam started the first biotech company in Texas and subsequently took it public in the U.S. Dr. Lam was referred to as “The Father of Texas Biotechnology”. Dr. Lam also founded LifeTech Group to develop and market healthcare products. In 1989, Dr. Lam received the Presidential Medal of Merit from President Bush for his pioneering work in biotechnology. He was appointed Member of the President’s Inner Circle, an advisory group to the U.S. President. On December 18, 1999, Dr. Lam founded the World Eye Organization (WEO) to prevent and treat eye diseases for the poor; and in 2001, Dr. Lam’s patent on “Edible Vaccine” was named by MIT as one of “five patents that will transform business and technology”, and by Time Magazine as one of ten most important inventions in the 21st century.
Mr. Arthur S. Reynolds has more than 35 years’ experience raising capital in Europe for clients located in the US. Mr. Reynolds is a Managing Director of Rexon Limited, which he founded in 1995 and through which he has since raised capital for more than 50 companies. Mr. Reynolds commenced his career with Mobil Corporation and W.R. Grace and Co. (-sold National Medical Care, world's largest operator of kidney disease treatment centers in 1996, to Fresenius A.G. for $4.4 billion). He joined Morgan Guaranty Trust Company’s Corporate Finance Department and later, he and others founded the Interfunding unit of J.P. Morgan & Co. In 1978, he began a 27-year career in London raising capital for US clients, first as an officer of Merrill Lynch International Bank Limited and subsequently, as the founder of Ferghana Financial Services Ltd in 1982, at the behest of Sir James Goldsmith for whose operations Mr. Reynolds raised more than $300 million. Mr. Reynolds served on the Board of Directors of ThermoEnergy Corporation, where he was Chairman of the Board from 2014-2016 and Chairman of the Audit Committee from 2001 to 2006 and again from 2009-2013.
Mr. Markus Müller is currently a member of the Board of Directors of Arundel AG, an investment services firm based in Zurich providing specialist investment banking and investment management as well as advisory services to family offices and fund management groups across developed and emerging markets. Mr. Müller commenced his professional career working for Credit Suisse. From 2000 to 2018, Mr. Müller served in the executive management of Scherrer & Partner Investment Management AG (Zurich), a company involved in asset management for private clients and the management of investment funds. From 1995 to 2000, Mr. Müller served in the management of Jefferies (Switzerland) Ltd and as the general manager of Jefferies Asset Management AG (Zug).
Educated at the Wharton School of the University of Pennsylvania (USA), Numair holds a business degree with concentrations in Finance and Marketing, and is a member of the National Association of Investment Managers (USA) and an Affiliated Professional (AP) with the Chartered Institute of Marketing (UK). During his education, he benefited from professional assignments within corporations like Citibank, American Express, and Jardine Fleming (now JP Morgan Chase). His professional experience encompasses both small start-ups (Zig Zag Net, USA) and major corporate setups like Shell (Pakistan), where, for varying durations, he worked in the Finance and Marketing functions, and Unisys (USA), where he consulted to industry players as well as the government. Since 2011, Numair has held various positions within the healthcare and pharmaceutical industries. He is the former Chief Operating Officer of BioVance, a clinical research organization with strong links in the UK & Pakistan, the former CEO of Hye Noon Technologies, which focuses on IT products & solutions targeting specific issues faced by pharmaceutical companies, and Head of Corporate Affairs & Company Secretary for Pharmatec, a large contract manufacturer for multinational pharmaceutical companies, where he specializes in group restructuring, asset protection, and corporate governance initiatives.
Mr. Kaiser has a degree in Economics from the Hoeheren Wirtschafts- und Verwaltungsschule, St. Gallen, Switzerland. He also holds the degrees of Swiss Financial Analyst & Portfolio Manager as well as Certified International Investment Analyst. Mr. Kaiser has over 25 years of experience in financial markets, having worked as securities dealer, fund and asset manager at major Liechtenstein banks and investment companies. From 2002 to 2013 Mr. Kaiser served as a managing director with Regent Fund Management Limited. Currently, he serves as managing director of Consortium Asset Management Establishment and of BlueRidge Management AG, which is a fiduciary and trust company in Liechtenstein.